
Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean (“ABO”), previously announced on July 21, 2022.
Since its creation in 2017, ABO has executed more than $1.5 billion in financial commitments and more than 90 transactions, mostly within the life sciences sector, all around the globe.